A Functional Assay for the Determination of Heparin-Induced Thrombocytopenia via Flow Cytometry.
heparin-induced thrombocytopenia (HIT)
heparin–PF4 complex (platelet factor 4)
immunological and functional assays
serotonin release assay (SRA)
Journal
Diagnostics (Basel, Switzerland)
ISSN: 2075-4418
Titre abrégé: Diagnostics (Basel)
Pays: Switzerland
ID NLM: 101658402
Informations de publication
Date de publication:
21 Sep 2023
21 Sep 2023
Historique:
received:
27
06
2023
revised:
18
09
2023
accepted:
19
09
2023
medline:
28
9
2023
pubmed:
28
9
2023
entrez:
28
9
2023
Statut:
epublish
Résumé
Heparin-induced thrombocytopenia (HIT) is a life-threatening complication of heparin therapy (both unfractionated heparin and low-molecular-weight heparin). In our study, we examined a group of 122 patients with suspected HIT. The samples of all patients were analyzed in the first step using an immunoassay (ID-PaGIA Heparin/PF4, Hemos1L-Acustar HIT IgG, ZYMUTEST HIA Monostrip IgG) to detect the presence of antibodies against heparin-PF4 complexes (platelet factor 4). When the immunoassay was positive, the sample was subsequently analyzed for HIT with a functional flow cytometry assay, the HITAlert kit, the purpose of which was to demonstrate the ability of the antibodies present to activate platelets. A diagnosis of HIT can be made only after a positive functional test result. In this article, we present an overview of our practical experience with the use of the new functional method of analysis, HIT, with flow cytometry. In this work, we compared the mutual sensitivity of two functional tests, SRA and the flow cytometry HITAlert kit, in patients perceived as being at risk for HIT. This work aims to delineate the principle, procedure, advantages, pitfalls, and possibilities of the application of the functional test HITAlert using flow cytometry.
Identifiants
pubmed: 37761386
pii: diagnostics13183019
doi: 10.3390/diagnostics13183019
pmc: PMC10527925
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
Hematol Rep. 2021 Mar 12;13(1):8857
pubmed: 33747413
Blood. 2020 Apr 2;135(14):1171-1184
pubmed: 31945147
Expert Rev Hematol. 2021 Apr;14(4):335-346
pubmed: 33736552
J Am Coll Cardiol. 2016 May 31;67(21):2519-32
pubmed: 27230048
J Community Hosp Intern Med Perspect. 2022 Jul 04;12(4):102-106
pubmed: 36262902
Am J Hematol. 2018 Feb;93(2):308-314
pubmed: 29164662
J Thromb Haemost. 2007 Nov;5(11):2308-10
pubmed: 17697138
Curr Hematol Rep. 2003 Mar;2(2):148-57
pubmed: 12901146
Cytometry A. 2008 Oct;73(10):926-30
pubmed: 18752282
J Thromb Haemost. 2006 Apr;4(4):759-65
pubmed: 16634744
J Thromb Haemost. 2007 Aug;5(8):1666-73
pubmed: 17488345
N Engl J Med. 2015 Jul 16;373(3):252-61
pubmed: 26176382
Arch Intern Med. 2003 Nov 10;163(20):2518-24
pubmed: 14609790
Blood Coagul Fibrinolysis. 2013 Jun;24(4):365-70
pubmed: 23429257
Molecules. 2017 Apr 11;22(4):
pubmed: 28398258
Br J Haematol. 1997 Sep;98(3):648-56
pubmed: 9332321
Blood Adv. 2018 Nov 27;2(22):3360-3392
pubmed: 30482768
Blood. 2012 Nov 15;120(20):4160-7
pubmed: 22990018
Blood. 2012 Mar 8;119(10):2209-18
pubmed: 22246036
J Cardiovasc Dev Dis. 2021 Nov 25;8(12):
pubmed: 34940516
Am J Hematol. 2021 Mar 1;96(3):320-329
pubmed: 33326124
Biomedicines. 2021 Mar 25;9(4):
pubmed: 33806140
J Crit Care. 2014 Jun;29(3):470.e7-15
pubmed: 24726205
Chest. 2004 Sep;126(3 Suppl):311S-337S
pubmed: 15383477
Biomedicines. 2021 Mar 13;9(3):
pubmed: 33805718
Vasc Med. 2020 Apr;25(2):160-173
pubmed: 32195628
Am J Hematol. 1999 May;61(1):53-61
pubmed: 10331512
Blood. 2015 Jul 30;126(5):597-603
pubmed: 25926600
Blood. 2017 May 25;129(21):2864-2872
pubmed: 28416511